Dataset Information

Exploring bioactive peptides from bacterial secretomes using PepSAVI-MS: identification and characterization of Bac-21 from Enterococcus faecalis pPD1

ABSTRACT: Background. As current methods for antibiotic drug discovery are being outpaced by the rise of antimicrobial resistance, new methods and innovative technologies are necessary to replenish our dwindling arsenal of antimicrobial agents. To this end, we developed the PepSAVI-MS pipeline to expedite the search for natural product bioactive peptides. Results. Herein we demonstrate expansion of PepSAVI-MS for the discovery of bacterial-sourced bioactive peptides through identification of the bacteriocin Bac-21 from Enterococcus faecalis pPD1. Minor pipeline modifications including implementation of bacteria-infused agar diffusion assays and optional digestion of peptide libraries highlight the versatility and wide adaptability of the PepSAVI-MS pipeline. Additionally, we have experimentally validated the primary protein sequence of the active, mature Bac-21 peptide for the first time and have confirmed identity with respect to primary sequence and post-translational processing. Conclusions: Successful application of PepSAVI-MS to bacterial secretomes as demonstrated herein establishes proof-of-principle for use in novel microbial bioactive peptide discovery.

INSTRUMENT(S): LTQ Orbitrap, TripleTOF 5600

ORGANISM(S): Enterococcus Faecalis (streptococcus Faecalis)

SUBMITTER: Christine Kirkpatrick

LAB HEAD: Leslie M. Hicks

PROVIDER: PXD009003 | Pride | 2018-07-23

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20170614_EFSCXfractions.R	Other
	20180110_CLK_BAP_EF_RAD_37_10uL.mgf	Mgf
	20180110_CLK_BAP_EF_RAD_37_10uL.pride.mgf.gz	Mgf
	20180110_CLK_BAP_EF_RAD_37_10uL.wiff	Wiff
	20180110_CLK_BAP_EF_RAD_37_10uL.wiff.scan	Wiff

Items per page:

1 - 5 of 113

Publications

Exploring bioactive peptides from bacterial secretomes using PepSAVI-MS: identification and characterization of Bac-21 from Enterococcus faecalis pPD1.

Kirkpatrick Christine L CL Parsley Nicole C NC Bartges Tessa E TE Wing Casey E CE Kommineni Sushma S Kristich Christopher J CJ Salzman Nita H NH Patrie Steven M SM Hicks Leslie M LM

Microbial biotechnology 20180716 5

As current methods for antibiotic drug discovery are being outpaced by the rise of antimicrobial resistance, new methods and innovative technologies are necessary to replenish our dwindling arsenal of antimicrobial agents. To this end, we developed the PepSAVI-MS pipeline to expedite the search for natural product bioactive peptides. Herein we demonstrate expansion of PepSAVI-MS for the discovery of bacterial-sourced bioactive peptides through identification of the bacteriocin Bac-21 from Entero ...[more]

PMID: 30014612

Similar Datasets

Project description:Human histomonocytic U937 cells exhibit macrophage-like properties after phorbol ester stimulation. Accumulating evidence demonstrated that remarkable number of transcripts changed in their amount at total RNA levels. However, post-transcriptional regulation has not been fully elucidated in this model. Thus, we compared expression profiles between polysomal and cytoplasmic RNAs before and after phorbol 12-myristate 13-acetate stimulation (48h, 32nM). Table 1: Detailed description of the expression data of human histomonocytic cell line U937 cells. Data of total cytoplasmic and polysomal fractions before and after PMA stimulation is shown. This table contains all spot data except: 1) saturated spots, 2) undetectable spots, 3) stained spots, and 4) spots only detected in less than one samples. Column A: Gene symbol (âI_xxxxxxâ is corresponding to EST clones); Column B: Genbank accession no. Column C: Description; Column D: Average value of expression levels in total cytoplasmic fraction in the absence of PMA; Column E: Average value of expression levels in total cytoplasmic fraction in the presence of PMA (32nM, 48h); Column F: Average value of expression levels in polysomal fraction in the absence of PMA; Column G: Average value of expression levels in polysomal fraction in the presence of PMA; Column H: Expression ratio of polysome, PMA (-) to cytoplasm, PMA(-); Column I: Expression ratio of polysome, PMA (+) to cytoplasm, PMA(+); Column J: Expression ratio of cytoplasm, PMA (+) to cytoplasm, PMA(-); Column K: Expression ratio of polysome, PMA (+) to polysome, PMA(-); Column L: Different expression between polysome, PMA (-) and cytoplasm, PMA(-): different=1; Column M: Different expression between polysome, PMA (+) and cytoplasm, PMA(+): different=1; Column N: Different expression between cytoplasm, PMA (+) and cytoplasm, PMA(-): different=1; Column O: Different expression between polysome, PMA (+) and polysome, PMA(-): different=1; ; Table 2: Candidates post-transcriptionally regulated by PMA. We extracted 105 transcripts whose expression levels were altered only in either fraction accompanied by changes in polysome/cytoplasm expression ratio. Column A: Gene symbol (âI_xxxxxxâ is corresponding to EST clones); Column B: Genbank accession no. Column C: Description; Column D: Average value of expression levels in total cytoplasmic fraction in the absence of PMA; Column E Average value of expression levels in total cytoplasmic fraction in the presence of PMA; Column F: Average value of expression levels in polysomal fraction in the absence of PMA; Column G: Average value of expression levels in polysomal fraction in the presence of PMA; Column H: Expression ratio of polysome, PMA (-) to cytoplasm, PMA(-); Column I: Expression ratio of polysome, PMA (+) to cytoplasm, PMA(+); Column J: Expression ratio of cytoplasm, PMA (+) to cytoplasm, PMA(-); Column K: Expression ratio of polysome, PMA (+) to polysome, PMA(-)

Project description:N6,2'-O-dimethyladenosine (m6Am) is a critical and reversible RNA modification that plays a significant role in regulating RNA stability and gene expression. However, the lack of precise tools for manipulating m6Am modifications on specific transcripts has hindered the ability to elucidate the relationship between m6Am-modified transcripts and their phenotypic outcomes. Here, we present a CRISPR-Cas13d-based tool for the targeted installation of m6Am modifications on specific RNA transcripts. This tool is engineered by fusing a catalytically inactive variant of RfxCas13d (dCasRx) with the m6Am methyltransferase PCIF1. The dCasRx-PCIF1 fusion protein enables precise methylation of target m6Am-modified RNAs. We demonstrate that INSTALLER can effectively install m6Am modifications on GAPDH and ACTB RNAs, significantly enhancing their stability. MTD keywords Human, HEK293T cells MTD sample_processing_protocol Protein extraction and tryptic digestion. Cell lysates were lysed in lysis buffer (RPIA) supplemented with protease inhibitors and phosphatase inhibitors for 30 min. Then they were sonicated by grinding instrument at 4 ℃ and centrifuged at 12000 rpm for 15 min to remove the tissue debris. The protein in supernatants were collected and measured by using BCA protein assay. Next, 20 mM Tris (2-chloroethyl) phosphate (TCEP) was added to the protein solution to react at 60℃ for 1 h. After that, 200 mM Chloroacetamide (CAA) was added to the mixture and react at room temperature for 30 min in darkness. After the reaction, ice-cold acetone was used to precipitate the protein at -20℃ for 4 h. The pellet was air-dried and then resuspended in 150 μl 0.1M ABB. Protein samples underwent trypsin digestion (enzyme-to-substrate ratio of 1:25 at 37 ℃for 16 hours) followed by desalting through sola HRP cartridges and vacuum- dried by Speed Vac. Nano-LC-MS/MS analysis. Peptide samples were analyzed by an EASY-nLC 1200 LC system coupled with Orbitrap mass spectrometry (Thermo Fisher). The column was C18 nano-capillary analytical column (25 cm*75 mm, 1.9 μm). Peptides were re-dissolved in mobile phase A (Water/CAN/formic acid, 98/2/0.1, v/v). The gradient was 0-5 min, 5-10% B; 5-55 min, 10-28% B; 55-58 min, 28-40% B，58-63 min, 40-95% B; 63-75 min; 95% B with flow rate of 350 nL/min. Mass spectrometry was operated under a data independent acquisition mode (DIA). The m/z range was 350 to 1500 Da in MS1 with the resolution of 60,000. The automatic gain control (ACG) was set as 3e6. The maximal ion injection time was 50 ms. MS2 acquisition was higher energy collision dissociation (HCD) with the collision energy of 30 eV. The resolution was 30,000, with loop count set to: 25, MSX count set to: 1, isolation window set to: 8.3m/z, fixed maximum mass set to: 200m/z, respectively.

Project description:The need for an efficient carcinogenicity test prompted this study, in which we used a microarray-based genomics approach, with a short-term in vivo model, in combination with insights from statistical and mechanistic analyses. We performed additional experiments to support the significance of the microarray results. Carcinogens were evaluated based on differences in the mechanisms involved in the response to genotoxic (GTX) carcinogens and non-genotoxic (NGTX) carcinogens. Microarray data were analyzed for 2 time points after treatment with the following 6 carcinogens. The analysis was performed using t-tests to compare the fold changes, and we selected differentially expressed genes (DEGs) and evaluated the reasons for differential expression in terms of cellular pathways and processes. We mapped the DEG-related pathways to analyze cellular processes, and we were able to uncover significant mechanisms that involve critical cellular components, such as CDKN1A (p21) and BAX. In addition, a comparison of the data from two time points showed that the repeated administration model was more effective than a single administration for carcinogen research. The classification analysis of selected DEGs was performed by setting microarray data of 4 carcinogens as test sets; these test sets were evaluated as classifiers. Microarray results were further supported using the Comet and micronucleus assays. It was found that gene expression profiling using microarrays, followed by pathway analysis, was effective in increasing the understanding of the characteristics of different carcinogens, and the efficiency of these methods was exemplified by the short-term (3 day) nature of the animal experiments. The following 10 hepatocarcinogens were used: 2-acetylaminofluorene (53-96-3), diethylnitrosamine (55-18-5), 4-dimethylamino-3'-methyl azobenzene (55-80-1), clofibrate (637-07-0), 1,4-dioxane (123-91-1), DL-ethionine (67-21-0), 1,3-dichloro-2'-propanol (96-23-1), urethane (51-79-6), sodium nitrite (7632-00-0), and methyleugenol (93-15-2). Forty-one data were obtained for the training compounds in this study. We treated rats with one of three compounds or a control for each GTX and NGTX experimental group and measured 2 time points for each group. All experimental procedures were repeated three times. We excluded 1 file that was found to be a failure. Each ‘.CEL’ file obtained as a raw data file was standardized using the RMA (Robust Multi-array Average) algorithm.